Table 1 Baseline demographic, clinical and neurological characteristics of subjects and number of motor test acquisitions
Total | p-iNPH | v-iNPH | |
|---|---|---|---|
Demographic | |||
Subjects | 76 | 56 | 20 |
Males (%) | 43 (57) | 31 (55) | 12 (60) |
Mean age at disease onset (st. Dev) | 72 (5.7) | 71 (6.2) | 73 (3.3) |
Mean age at evaluation (st. Dev) | 75 (4.7) | 74 (5.1) | 77 (3.0) |
Disease duration < 12 months | 21 | 18 | 3 |
Disease duration > 12 months | 55 | 38 | 17 |
BMI, [kg/m2] (st. Dev) | 27 (4.1) | 28 (3.9) | 25 (4.1) |
Clinical profile | |||
Symptoms at first evaluation | |||
1, subjects (%) | 6 (8) | 6 (11) | 0 |
2, subjects (%) | 18 (24) | 13 (23) | 5 (25) |
3, subjects (%) | 52 (68) | 37 (66) | 15 (75) |
gait disorders, subjects (%) | 76 (100) | 56 (100) | 20 (100) |
urinary dysfunctions, subjects (%) | 63 (83) | 47 (84) | 16 (80) |
cognitive impairments, subjects (%) | 58 (76) | 39 (70) | 19 (95) |
Number of falls in the last 6 months | |||
0, (%) | 17 (22) | 12 (21) | 5 (25) |
1, (%) | 15 (20) | 12 (21) | 3 (15) |
≥ 2, (%) | 44 (58) | 32 (57) | 12 (60) |
Mean ARWMC (st. Dev) | 7.2 (4.6) | 5.0 (2.7) | 13.7 (2.3) |
Motor tests | |||
TUG total trials acquired | 585 | 405 | 180 |
TUG discarded (incomplete acquisitions) | 31 (5%) | 22 (5%) | 9 (5%) |
18 mW total trials acquired | 405 | 300 | 135 |
18 mW discarded (incomplete acquisitions) | 32 (8%) | 21 (7%) | 11 (8%) |